Anti-TNFα therapy in the management of psoriasis: experience of a state referral center

BACKGROUND:Psoriasis is a chronic immune-mediated disease, characterized by increased levels of TNFα. Anti-TNFα agents have revolutionized the treatment of severe psoriasis by targeting an important molecule involved in its pathogenesis.OBJECTIVES:We report the experience of a state referral center...

Full description

Bibliographic Details
Main Authors: Laura Maria Andrade Silva, Bruno de Oliveira Rocha, Ana Cláudia Pinto Nobre, Vitória Regina Pedreira de Almeida Rêgo, Ivonise Follador, Maria de Fátima Santos Paim de Oliveira
Format: Article
Language:English
Published: Sociedade Brasileira de Dermatologia 2014-06-01
Series:Anais Brasileiros de Dermatologia
Subjects:
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962014000300436&tlng=en
_version_ 1798020327348895744
author Laura Maria Andrade Silva
Bruno de Oliveira Rocha
Ana Cláudia Pinto Nobre
Vitória Regina Pedreira de Almeida Rêgo
Ivonise Follador
Maria de Fátima Santos Paim de Oliveira
author_facet Laura Maria Andrade Silva
Bruno de Oliveira Rocha
Ana Cláudia Pinto Nobre
Vitória Regina Pedreira de Almeida Rêgo
Ivonise Follador
Maria de Fátima Santos Paim de Oliveira
author_sort Laura Maria Andrade Silva
collection DOAJ
description BACKGROUND:Psoriasis is a chronic immune-mediated disease, characterized by increased levels of TNFα. Anti-TNFα agents have revolutionized the treatment of severe psoriasis by targeting an important molecule involved in its pathogenesis.OBJECTIVES:We report the experience of a state referral center that uses anti-TNFα agents for psoriasis.METHODS:We conducted a retrospective case series. Seventy-four out of 120 patients met the inclusion criteria. Clinical and laboratory data was analyzed using the chi-squared, Wicoxon and McNemar's tests. Associations were considered statistically significant when p-value<0.05.RESULTS:Forty-one subjects (55.40%) were male, with a mean age of 47.69±14.99 years. Median disease duration and pre-treatment PASI were 14.0 months (IQR 9.0-20.0), and 13.55 points (IQR 8.5-20.32). Sixty patients (81.10%) had arthropathic psoriasis. Forty-six subjects (62.20%) had comorbidities; the most frequent was dyslipidemia (25.70%). In 55.40% of patients, insufficient response to conventional therapies was the principal indication for using anti-TNFα drugs. Clinical improvement occurred in 93.20% of cases, and the post-treatment PASI median was 0.0 points (IQR 0.0-0.0). Adverse effects occurred in 6.80% of patients. Infections and elevation of transaminases occurred in 28.40% and 8.10% of cases, respectively.CONCLUSION:Post-treatment reduction in PASI was satisfactory and the occurrence of adverse effects was minor, mostly mild infusion effects and local reactions at drug administration sites.
first_indexed 2024-04-11T16:55:49Z
format Article
id doaj.art-b2233cf5239a42399d1d1ab8ef3ea8e0
institution Directory Open Access Journal
issn 0365-0596
language English
last_indexed 2024-04-11T16:55:49Z
publishDate 2014-06-01
publisher Sociedade Brasileira de Dermatologia
record_format Article
series Anais Brasileiros de Dermatologia
spelling doaj.art-b2233cf5239a42399d1d1ab8ef3ea8e02022-12-22T04:13:16ZengSociedade Brasileira de DermatologiaAnais Brasileiros de Dermatologia0365-05962014-06-0189343644010.1590/abd1806-4841.20142613Anti-TNFα therapy in the management of psoriasis: experience of a state referral centerLaura Maria Andrade SilvaBruno de Oliveira RochaAna Cláudia Pinto NobreVitória Regina Pedreira de Almeida RêgoIvonise FolladorMaria de Fátima Santos Paim de OliveiraBACKGROUND:Psoriasis is a chronic immune-mediated disease, characterized by increased levels of TNFα. Anti-TNFα agents have revolutionized the treatment of severe psoriasis by targeting an important molecule involved in its pathogenesis.OBJECTIVES:We report the experience of a state referral center that uses anti-TNFα agents for psoriasis.METHODS:We conducted a retrospective case series. Seventy-four out of 120 patients met the inclusion criteria. Clinical and laboratory data was analyzed using the chi-squared, Wicoxon and McNemar's tests. Associations were considered statistically significant when p-value<0.05.RESULTS:Forty-one subjects (55.40%) were male, with a mean age of 47.69±14.99 years. Median disease duration and pre-treatment PASI were 14.0 months (IQR 9.0-20.0), and 13.55 points (IQR 8.5-20.32). Sixty patients (81.10%) had arthropathic psoriasis. Forty-six subjects (62.20%) had comorbidities; the most frequent was dyslipidemia (25.70%). In 55.40% of patients, insufficient response to conventional therapies was the principal indication for using anti-TNFα drugs. Clinical improvement occurred in 93.20% of cases, and the post-treatment PASI median was 0.0 points (IQR 0.0-0.0). Adverse effects occurred in 6.80% of patients. Infections and elevation of transaminases occurred in 28.40% and 8.10% of cases, respectively.CONCLUSION:Post-treatment reduction in PASI was satisfactory and the occurrence of adverse effects was minor, mostly mild infusion effects and local reactions at drug administration sites.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962014000300436&tlng=enPsoriatic arthritisPsoriasisTumor necrosis factor-alpha
spellingShingle Laura Maria Andrade Silva
Bruno de Oliveira Rocha
Ana Cláudia Pinto Nobre
Vitória Regina Pedreira de Almeida Rêgo
Ivonise Follador
Maria de Fátima Santos Paim de Oliveira
Anti-TNFα therapy in the management of psoriasis: experience of a state referral center
Anais Brasileiros de Dermatologia
Psoriatic arthritis
Psoriasis
Tumor necrosis factor-alpha
title Anti-TNFα therapy in the management of psoriasis: experience of a state referral center
title_full Anti-TNFα therapy in the management of psoriasis: experience of a state referral center
title_fullStr Anti-TNFα therapy in the management of psoriasis: experience of a state referral center
title_full_unstemmed Anti-TNFα therapy in the management of psoriasis: experience of a state referral center
title_short Anti-TNFα therapy in the management of psoriasis: experience of a state referral center
title_sort anti tnfα therapy in the management of psoriasis experience of a state referral center
topic Psoriatic arthritis
Psoriasis
Tumor necrosis factor-alpha
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962014000300436&tlng=en
work_keys_str_mv AT lauramariaandradesilva antitnfatherapyinthemanagementofpsoriasisexperienceofastatereferralcenter
AT brunodeoliveirarocha antitnfatherapyinthemanagementofpsoriasisexperienceofastatereferralcenter
AT anaclaudiapintonobre antitnfatherapyinthemanagementofpsoriasisexperienceofastatereferralcenter
AT vitoriareginapedreiradealmeidarego antitnfatherapyinthemanagementofpsoriasisexperienceofastatereferralcenter
AT ivonisefollador antitnfatherapyinthemanagementofpsoriasisexperienceofastatereferralcenter
AT mariadefatimasantospaimdeoliveira antitnfatherapyinthemanagementofpsoriasisexperienceofastatereferralcenter